Astex

Astex Pharmaceuticals, formerly SuperGen, fights for a better way to treat cancer. The company focuses on compounds in preclinical and early-stage clinical development. Its development pipeline includes candidates aiming to treat conditions such as lung cancer and leukemia. Astex Pharmaceuticals also has preclinical cancer research programs conducted in partnership with GlaxoSmithKline. Past successes include cancer compound Dacogen, which is licensed to Eisai. The company, which changed its name after acquiring UK drug developer Astex Therapeutics in 2011, plans to move its research operations to the UK while keeping its development and regulatory operations in the US.